Standing Order
Viking Therapeutics, Inc.

Dashboard

Viking Therapeutics, Inc.

VKTXNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$3.2B
Price$24.7752w $23.09 – $42.13
Conviction3/ 5
Revenue (TTM)$0
Revenue growth YoY—
P/E (trailing)—
Gross margin—
Operating margin—
Net margin—
52w price change-5.2%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 16
    Trial initiationClinicalTrials.gov

    Phase 3 SUNRISE 1 trial (NCT07868835) of oral VK2735 for weight management updated to recruiting status.

  • Nov 16
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07868939 (SUNRISE 2) of oral VK2735 for weight management in T2DM now recruiting.

  • Oct 28
    Financial resultsSEC

    VKTX 8-K (items 2.02, 9.01) reports results of operations.

  • Oct 16
    Trial initiationClinicalTrials.gov

    Phase 3 trial (SUNRISE 2) of oral VK2735 for weight management in Type 2 diabetes listed as not yet recruiting.

  • Oct 16
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07868835 (SUNRISE 1) for oral VK2735 weight management listed as not yet recruiting.

  • Oct 9
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07868939 (SUNRISE 2) of oral VK2735 for weight management in T2DM updated to not yet recruiting.

  • Oct 9
    Trial initiationClinicalTrials.gov

    Phase 3 trial (SUNRISE 1) of oral VK2735 for weight management listed as not yet recruiting.

  • Sep 29
    Trial initiationClinicalTrials.gov

    Viking Therapeutics initiates Phase 1 trial of VK3019 in overweight and obese adults (NCT07846033).

  • Sep 28
    DealSEC

    8-K filing disclosing entry into material definitive agreement and creation of direct financial obligation (items 1.01, 2.03).

  • Sep 25
    Securities offeringSEC

    SEC Form 424B5 filed: prospectus supplement for securities offering.

  • Sep 25
    Securities offeringSEC

    VKTX filed Form 424B5 prospectus supplement for securities offering.

  • Sep 24
    Trial initiationClinicalTrials.gov

    Phase 1 trial NCT07838740 of VK2735 in obese adults without comorbidities status updated to recruiting.

  • Sep 23
    Securities offeringSEC

    Form 424B5 securities offering prospectus supplement filed.

  • Sep 23
    Securities offeringSEC

    424B5 prospectus supplement filed for securities offering.

  • Sep 22
    OtherSEC

    Viking Therapeutics files 8-K covering items 8.01 and 9.01.

  • Aug 7
    Ownership changeSEC

    SEC Form 4 insider transaction filing

  • Jul 30
    Securities offeringSEC

    Filed Form S-3ASR automatic shelf registration statement with SEC.

  • Jul 29
    Financial resultsSEC

    Viking Therapeutics files 8-K (items 2.02, 9.01) disclosing financial results.

  • Jul 29
    Ownership changeSEC

    SEC Form 4 filing reporting insider ownership change.

  • Jul 29
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

Not financial advice — research and opinion only. Disclosures